Linear growth deficiency in β-thalassemia patients: Is it growth hormone dependent?

Iranian Journal of Medical Sciences

Volumn 27, Issue 2, 2002, Pages 47-50

  Karamifar, H ^a   Shahriari, M ^a   Amirhakimi, Gh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Growth hormone; L Dopa test; Thalassemia major

Indexed keywords

FERRITIN; GROWTH HORMONE; LEVODOPA;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BODY HEIGHT; BODY WEIGHT; CHELATION THERAPY; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROVOCATION TEST; QUESTIONNAIRE; SHORT STATURE;

EID: 0036625938     PISSN: 02530716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Grundy RG, Woods KA, Savage MO, et al: Relationship of endocrinopathy to iron chelation status in young patients with thalassemia major. Arch Dis Child 1994; 71: 128-32.
2. Sklar CA, Lew LQ, Yoon DJ, et al: Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. AJDC 1987; 141: 327-30.
3. Low LC: Growth, puberty and endocrine function in beta-thalassemia major: J Pediatr Endocrinol Metab 1997; 10(2): 175-84.
4. Pintor C, Cella SG, Manso P, et al: Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986; 62: 263-7.
5. Cavallo L, Gurrado R, Gallo F, et al: Growth deficiency in Polytransfused β-thalassemia patients is not growth hormone dependent. Clinical Endocrinology 1997; 46: 701-6.
6. Sabato AR, De Sanctis V, Atti G, et al: Primary hypothyroidism and the low T3 syndrome in thalassemia major. Arch Dis Child 1983; 58: 120-4.
7. Costin G, Kogut M, Hyman CB, et al: Endocrine abnormalities in thalassemia major. AJDC 1979; 133: 497-502.
8. Gulati R, Bhatia V, Agarwal SS: Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab 2000; 13: 651-6.
9. Costin G, Kogut M, Hymen C, et al: Carbohydrate metabolism and pancreatic islet cell function in thalassemia major. Diabetes 1977; 26: 230-40.
10. Gamberini MR, Fortini M, Gilli G, et al: Epidemiology and chelation therapy effects on glucose hemostasis in thalassemic patients. J Pediatr Endocrinol Metab 1998; 11 suppl: 3867-9.
11. Modell B, Letsky EA, Flynn DM, et al: Survival and desferrioxamine in thalassemia major. BMJ 1982; 284: 1081-4.
12. Mahoney P: Evaluating the child with short-stature. Pediatr Clin North AM 1987; 34: 825-46.
13. Pekrun RA, Bartz M, Jarry H, et al: Short stature and failure of pubertal development in thalassemia major: Evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997; 156: 777-83.
14. Masala A, Meloni T, Gallisai D, et al: Endocrine functioning in multitransfused prepubertal patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1984; 58: 667-70.
15. Mcintosh N: Endocrinopathy in thalassemia major. Arch Dis Child 1976; 51: 195-201.
16. Theodoridis C, Ladis V, Papatheodorou A, et al: Growth and management of short stature in thalassemia major. J Pediatr Endocrinol Metab 1998; 11 suppl: 3835-44.